Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
Top Cited Papers
- 11 March 2012
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 18 (4) , 605-611
Abstract
Drugs that induce redifferentiation of cancer cells are efficient only in some subtypes of AML. The authors show that sensitivity to pro-differentiation drugs such as ATRA can be induced by co-treatment with epigenetic drugs. An inhibitor of histone demethylase, LSD1, safely used as an antidepressant in humans, reprograms AML cells and makes them sensitive to the effects of ATRA in vitro and in vivo, suggesting that epigenetic interventions can increase response to cancer treatments. Acute promyelocytic leukemia (APL), a cytogenetically distinct subtype of acute myeloid leukemia (AML), characterized by the t(15;17)-associated PML-RARA fusion, has been successfully treated with therapy utilizing all-trans-retinoic acid (ATRA) to differentiate leukemic blasts. However, among patients with non-APL AML, ATRA-based treatment has not been effective. Here we show that, through epigenetic reprogramming, inhibitors of lysine-specific demethylase 1 (LSD1, also called KDM1A), including tranylcypromine (TCP), unlocked the ATRA-driven therapeutic response in non-APL AML. LSD1 inhibition did not lead to a large-scale increase in histone 3 Lys4 dimethylation (H3K4me2) across the genome, but it did increase H3K4me2 and expression of myeloid-differentiation–associated genes. Notably, treatment with ATRA plus TCP markedly diminished the engraftment of primary human AML cells in vivo in nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice, suggesting that ATRA in combination with TCP may target leukemia-initiating cells. Furthermore, initiation of ATRA plus TCP treatment 15 d after engraftment of human AML cells in NOD-SCID γ (with interleukin-2 (IL-2) receptor γ chain deficiency) mice also revealed the ATRA plus TCP drug combination to have a potent anti-leukemic effect that was superior to treatment with either drug alone. These data identify LSD1 as a therapeutic target and strongly suggest that it may contribute to AML pathogenesis by inhibiting the normal pro-differentiative function of ATRA, paving the way for new combinatorial therapies for AML.Keywords
This publication has 38 references indexed in Scilit:
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaNature, 2011
- (Bis)urea and (Bis)thiourea Inhibitors of Lysine-Specific Demethylase 1 as Epigenetic ModulatorsJournal of Medicinal Chemistry, 2010
- Comparative Analysis of Small Molecules and Histone Substrate Analogues as LSD1 Lysine Demethylase InhibitorsJournal of the American Chemical Society, 2010
- Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced GenesClinical Cancer Research, 2009
- A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor geneBlood, 2009
- The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylationNature Genetics, 2008
- Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genesProceedings of the National Academy of Sciences, 2007
- Histone H3 Lysine 4 Demethylation Is a Target of Nonselective Antidepressive MedicationsChemistry & Biology, 2006
- Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1Cell, 2004
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997